You just read:

Monopar Therapeutics, Inc. Announces Acquisition of GPX-150, a Broad Spectrum Phase II Cancer Drug Candidate, Closing on $9.7M in Financing, and Filing of Form 10 Registration Statement

News provided by

Monopar Therapeutics, Inc.

Nov 14, 2017, 09:40 ET